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any of the body’s systems that function to
maintain optimal health and well-being decline with
advancing age. Aerobic capacity, muscle mass, and
strength all progressively decline with age.This loss of
muscle mass, or sarcopenia, and the accompanying
reduction in strength increase the risk of falls and their
complications, and for many individuals the associated
loss of physical functional capacity leads to increasing
difficulty in living independently. Complaints of poor
sleep are common in older populations. Insomnia
reduces quality of life and is often a factor in decisions to
seek health care. Sleep complaints often lead to over-
medication and sedation of the elderly, with the numer-
ous potential attendant problems, including increased
morbidity and mortality. Finally, cognition also declines
with advancing age,particularly those cognitive functions
that involve novel problem solving and psychomotor
processing speed, with its own related impact on the
older individual’s ability to function independently.
Interventions that could at least stabilize or possibly
improve functional capacity, sleep quality, and cognitive
function theoretically have the potential to prolong an
older individual’s ability to live independently,and inter-
est in their possible utility is growing rapidly.There is
increasing evidence that the functioning of many of these
systems may be improved through stimulation of the
“somatotrophic” or growth hormone (GH)–insulinlike
growth factor–I (IGF-I) axis.Levels of GH and IGF-I rise
rapidly at puberty, remain high during early adulthood,
and then decline progressively with aging.It has been sug-
gested that with age there is a “somatopause” of GH-
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Many of the body’s systems that function to maintain
optimal health and well-being decline with advancing
age. Aerobic capacity, muscle mass, and strength all pro-
gressively decline. Significant sleep disturbances are asso-
ciated with increases in morbidity and mortality. Cogni-
tion declines, impacting an older individual’s ability to
function independently. Interventions that could at least
stabilize or possibly improve functional capacity, sleep
quality, and cognitive function have the theoretical
potential to prolong an older individual’s ability to live
independently, and interest in their possible utility is
growing rapidly. One such intervention may be stimula-
tion of the “somatotrophic” axis via growth hor-
mone–releasing hormone (GHRH). Here we review the
evidence for such somatotrophic interventions. We also
report preliminary findings on the effects of chronic
GHRH treatment on the somatotrophic hormones, body
composition, functional status, sleep, and cognitive func-
tion of healthy older men and women from two major
GHRH intervention studies, one recently completed and
the other ongoing.
MIGF-I anabolic status in both sexes,which is reversible by
GH restoration or stimulation therapies. Because the
aging pituitary remains capable of synthesizing and
secreting increased amounts of GH if appropriately stim-
ulated, several recent studies have examined the effects
of administering GH secretagogues (GHSs)—factors that
stimulate GH secretion—as an alternative to GH treat-
ment.These secretagogues include analogs of the endoge-
nous hypothalamic GHS,growth hormone–releasing hor-
mone (GHRH).
Here we briefly review the evidence for such soma-
totrophic interventions.We also report preliminary find-
ings on the effects of chronic GHRH treatment on the
somatotrophic hormones,body composition,functional
status,sleep,and cognitive function of healthy older men
and women from two major GHRH intervention stud-
ies,one recently completed and the other ongoing.
Aging, somatotrophic hormones, 
and body composition
GH is secreted by the pituitary under the hypothalamic
control of at least three peptide systems: somatostatin
(somatotropin-release inhibiting factor [SRIF]), which
inhibits GH secretion; GHRH; and a second recently
characterized secretagogue, ghrelin.
1 The combined
influences of these systems yield a pulsatile pattern of
GH secretion in peripheral blood. GH exerts its effects
by binding to its own receptor as well as by stimulating
the synthesis of IGF-I.The liver is the primary contribu-
tor to levels of IGF-I in the systemic circulation, but
IGF-I is generated in many GH target tissues, and local
effects may be more important than those of circulating
IGF-I of hepatic origin.
1
With aging,there are declines in the GH-IGF-I axis
2 and
in lean body mass.
3 The amplitude of stimulated GH
release as well as integrated 24-hour GH levels have
been observed to decline with age.
4-8 Parallel declines in
IGF-I have also been observed by ourselves and oth-
ers.
4,9,10A variety of mechanisms could potentially under-
lie this decline in GH secretion with aging. Current evi-
dence suggests that this is most likely the result of both
a decrease in GHS activity and an increase in somato-
statin, but not an intrinsic loss of pituitary capacity to
secrete GH. Consequently, stimulation of the soma-
totrophic axis with GHRH is a potential alternative to
replacement with GH itself in normal aging.GHSs such
as GHRH may result in a more “physiological”stimulus
to GH secretion than GH per se. GHRH yields a pul-
satile GH secretion as opposed the continuously elevat-
ed levels seen with GH administration. Further, when a
secretagogue is used,the normal negative feedback reg-
ulation by IGF-I on pituitary GH secretion is preserved,
offering the possibility of reduced side effects.
The hypothesis that age-related decreases in IGF-I and
protein synthesis are due to an age-associated decrement
in GH secretion is supported by studies showing that
exogenous GH administration restores plasma IGF-I to
youthful levels in aged animals and humans.
11-13 Similarly,
IGF-I restores protein synthesis and lean body mass
(LBM) in animals and humans.
11,14,15Thus,the age changes
in the GH-IGF-I axis and LBM appear to be at least part-
ly reversible.
Aging, sleep, 
and somatotrophic hormones
Nearly 40% of the older (over 55 years) population suf-
fers from and complains of insomnia, fragmented sleep,
and poor sleep quality,more than any other age group.
16-19
Older individuals are twice as likely to complain of diffi-
culties falling asleep and remaining asleep, and of having
less restful sleep than younger individuals.These com-
plaints of poor sleep are supported by objective findings
in the sleep laboratory, which include: (i) a decrease in
stages 3 and 4 sleep (slow-wave sleep [SWS]),often called
“deep” sleep, and the delta electroencephalography
(EEG) activity that characterizes it;(ii) an increase in the
number of awakenings from sleep and an increase in the
total time spent awake; and (iii) a decrease in the rapid-
eye-movement (REM) sleep stage.We
20,21 and others have
shown that these disturbed sleep patterns are seen even in
optimally healthy, noncomplaining, elderly individuals
who have been carefully screened for possible medical
and psychological factors that might disrupt sleep.
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Selected abbreviations and acronyms
GH growth hormone
GHRH growth hormone–releasing hormone
GHS growth hormone secretagogue
IGF-I insulinlike growth factor–I
LBM lean body mass
REM rapid eye movement 
SWS slow-wave sleepThe public health burden associated with sleep distur-
bances in the elderly is considerable.These sleep distur-
bances have been linked to increased use of sedative
hypnotics,
22-25 greater use of the health services,
22,26-28 and
reduced functional ability and quality of life.
17,18,29,30 Fur-
ther, these sleep disturbances are frequently comorbid
with physical and mental illness,
22,28,31-34 are often a major
reason for nursing home placement,
35,36 and may predict
future declines in physical health and mortality.
35,37-42 The
consistent report of disturbed sleep
16,43 by the elderly
may account for the disproportionate prescription of
sedative hypnotics to the elderly population.
16,19 Hyp-
notic medication offers only short-term efficacy and, in
the long term, may itself disrupt sleep.
44,45 Hypnotic use
may also lead to exacerbation of sleep apnea and day-
time carryover effects, such as sedation, delirium, falls,
fractures,cognitive impairment,and anterograde amne-
sia
46 and has been associated with increased morbidity
and mortality.
35,37-42 The 1991 National Institutes of
Health (NIH) Consensus Conference on the Treatment
of Sleep Disorders of Older People concluded that
“nonsedative hypnotic approaches to improve sleep
quality in the elderly population are sorely needed.”
19
Pulsatile GH secretion continues with aging, but with a
pattern of diminished GH pulse amplitude.
4 In particu-
lar, nighttime GH secretion declines, so that there is
often no longer a clear night–day GH rhythm.SWS also
declines with aging, although it is unclear whether the
GH decline is due to the reduction in SWS, whether
SWS deteriorates because of the decline in GH, or
whether both are decreased because of a common
reduction at a higher level of regulation (eg, GHRH).
Recent studies have shown that sleep is influenced by
clinical extremes of GH status
47,48 and that sleep can be
improved in response to acute GH administration
49 or
stimulation of the GH-IGF-I axis using GHRH.
50Acute
GHRH administration increases SWS
51 and acute
decreases in GH status by a GH-releasing factor antag-
onist decrease slow-wave amplitude and SWS duration
52
in animals.Among hormones,GHRH displays the best-
documented sleep-promoting activity and is clearly
implicated in the regulation of sleep, specifically non-
REM sleep.GHRH hypothalamic neurons projecting to
the basal forebrain,specifically the medial preoptic area,
likely act directly to increase non-REM/SWS.
53 Three
independent laboratories have recently reported that
GHRH promotes sleep in healthy young subjects,
54-58
although two older studies reported no such effect
59,60
and there is some evidence to suggest that the impact of
GHRH on the sleep of the elderly may be weaker.
61,62
Aging, cognition, 
and somatotrophic hormones
While it has been extensively documented that significant
changes in several major areas of cognitive function devel-
op with advancing age,such declines do not develop uni-
formly.For example,some components of memory remain
relatively intact with advancing age (eg,primary or short-
term memory),while others do not (eg,secondary or long-
term memory). A major distinction that is useful for
describing those functions that are preserved versus
impaired by advancing age was proposed by Cattell,ie,the
concepts of crystallized versus fluid intelligence.
63 Crystal-
lized intelligence,or abilities dependent upon accumulat-
ed experience and education,such as general knowledge,
culture-specific rules,and formal verbal reasoning,are rel-
atively resistant to age-related decline. Conversely, fluid
intelligence,or abilities involving concept formation,rule
discovery, planning behavior, and nonverbal reasoning,
markedly decline with advancing age.Recently,Salthouse
and others have suggested that this age-related change in
fluid intelligence is at least partially the result of decreas-
es in mental processing speed.
64,65
It has been suggested that the declines in GH and IGF-I
observed with advancing age may contribute to the
impaired cognitive function associated with aging and
perhaps to that seen in neurodegenerative diseases such
as Alzheimer’s disease.
66-70 GH and IGF-I are present in
the cerebrospinal fluid and both have binding sites in the
central nervous system (CNS), particularly in the hip-
pocampus,a brain structure crucial to learning and mem-
ory.
71-73 Significant negative correlations have been
observed between advancing age and the density of GH
binding sites,particularly in the pituitary,hypothalamus,
and hippocampus.
74,75We and others have reported posi-
tive correlations between IGF-I and cognition in the
healthy elderly.
76,77 Further, impairments in cognitive
function have been reported in adults with either child-
hood- or adult-onset GH deficiency.
78,79 Finally, two
recent, placebo-controlled trials
80,81 of 6 to 24 months of
GH treatment in GH-deficient adults reported improved
cognitive function with GH replacement. However, it
should be noted that a third, similar, placebo-controlled
study
82 observed no such improvement after 18 months
of GH treatment.
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231Chronic GHRH treatment: 
preliminary results
Taken as a whole,the literature reviewed above suggests
that augmenting the somatotrophic axis with chronic
GHRH may have an impact not only on GH, IGF-I,
body composition,and therefore physical function status,
but also on CNS function, specifically sleep quality and
cognitive function.At the University of Washington, we
have been conducting two NIH-supported studies of the
effects of chronic GHRH administration on hormonal
and functional end points in healthy older women and
men.One recently completed study (grant number RO1-
AG10943 to R. S. Schwartz) assessed the combined
effects of 6 months’ treatment with GHRH or placebo
and an exercise intervention on body composition,
strength, and functional status in healthy older women
not taking estrogen replacement therapy.The second,
ongoing study (grant number RO1-MH53575 to M.V.
Vitiello) examined the effects of 5 months’ treatment
with GHRH or placebo on GH profiles, body composi-
tion,and functional status including sleep,cognition,and
physical function in healthy older men and women; this
trial is still in progress. Both studies involved the same
drug treatment: a single evening subcutaneous injection
of GHRH (14 µg/kg [≈1 mg] of GHRH(1-29)NH2, ser-
morelin acetate, Geref
®, Serono Laboratories Inc).
Because both of these studies  involve women on estro-
gen replacement therapy (ERT) and women not on
estrogen replacement therapy (NERT) as well as men,it
will ultimately be possible to examine not only gender
but also estrogen replacement status effects on the
impact of GHRH treatment.While one of these studies
is still ongoing and only preliminary results from both
studies have been reported to date,a few early,tentative
conclusions can be offered.
Somatotrophic hormones, body composition,
and physical function
These studies show that once-nightly doses of GHRH are
well tolerated and can significantly enhance GH secretion
and elevate IGF-I levels.They also demonstrate differ-
ences in responses among gender/estrogen replacement
groups, and limitations in current GHRH formulations.
The side effects typically reported in GH treatment stud-
ies, mainly peripheral edema and arthralgias, were very
uncommon.Rarely,GHRH-treated patients reported ery-
thema or swelling at the injection site.Male subjects dou-
bled their 24-h GH secretion and experienced a 40% rise
in IGF-I levels.
83 NERT women had a similar response,
with an average 30% increase in IGF-I levels over base-
line. ERT women had the most vigorous increase in GH
in response to GHRH,but,despite this,they experienced
the lowest IGF-I increments, averaging <10%. These
results suggest that oral estrogen replacement induces rel-
ative GH resistance.This last result is comparable to that
reported in estrogenized vs nonestrogenized adult
patients with GH deficiency receiving GH replacement.
84
While the significant increase in GH was maintained for
the duration of the treatment period,there are clear lim-
itations with the current GHRH formulation.A single,
large burst of GH secretion was observed immediately
following each evening injection.Nighttime pulsatile GH
secretion was not restored.Further,late-night GH secre-
tion was reduced compared with baseline GH profiles.
This could represent a temporary exhaustion of
releasable GH stores following the acute supraphysio-
logical effect, or negative feedback suppression by the
increased circulating levels of IGF-I.Daytime GH secre-
tion,while still low,was not suppressed,favoring the for-
mer explanation.The net effect of GHRH treatment is
the observed near-doubling of overall GH secretion and
a ≈40% increase in IGF-I.
Body composition measured by whole-body dual energy
x-ray absorptiometry (DEXA) scans shows a significant
decrease (≈5%) in percentage body fat in men and
NERT women, with a reciprocal increase in LBM.
83,85,86
As with the effect on IGF-I, the GHRH effect on body
composition is blunted in ERT women; it appears that
oral estrogen induces a resistance to GH action.This
blockade is qualitatively similar to the effect seen in ERT
GH-deficient women receiving GH treatment.
84
In these studies, physical function was assessed by both
standard measures of strength and a continuous-scale
physical functional performance (PFP) test developed at
the University of Washington.
87 The PFP is designed to
assess the higher capabilities of subjects living indepen-
dently and it has been shown to measure deterioration
in physical function, which was not clinically apparent,
over a 6-month period.PFP results for the current stud-
ies are very preliminary.The effects of GHRH appear to
vary by specific task,some showing improvement in the
actively treated group and no change in those receiving
placebo, while others show no change with GHRH and
deterioration with placebo.
85,88
Free paper
232Sleep quality and cognitive function
Both objective and subjective sleep are being measured
in the ongoing NIMH-funded study; however, prelimi-
nary data are currently available only for subjectively
rated sleep quality.The Pittsburgh Sleep Quality Index
(PSQI) is a self-rated questionnaire, which assesses
sleep quality and disturbances over a 1-month time
interval. Nineteen individual items generate seven
“component” scores: subjective sleep quality, sleep
latency, sleep duration, habitual sleep efficiency, sleep
disturbances, use of sleeping medication, and daytime
dysfunction.
89 The sum of the scores for these seven
components yields one global score with a maximum
possible score of 25.A global PSQI score greater than 5
has been shown to significantly distinguish good and
poor sleepers,although this criterion was not developed
on older subjects where higher scores are to be expect-
ed. Counterintuitively, GHRH treatment was associat-
ed with a very small but significant increase in PSQI
total score (4.1±2.8 vs 5.4±2.8,N=37, P<0.05) suggesting
that chronic GHRH resulted in poorer sleep.No change
in PSQI was noted for the placebo group (4.5±2.9 vs
4.6±2.7, N=38). Examination of the PSQI’s seven com-
ponent scores within the GHRH group revealed no
clear impact of GHRH treatment on any of the compo-
nents,suggesting that this may be a nonspecific finding.
The real significance of this small increase in subjec-
tively rated sleep quality remains unclear and awaits
analysis of the full study sample and the corresponding
analysis of objective sleep measures.
We  and others have reported positive correlations
between IGF-I and cognition in the healthy elderly.
76,77
In a previously published abstract of a study in 64
patients,
90 we reported that GHRH treatment resulted
in significantly improved performance (5% to 7%) rel-
ative to placebo on several cognitive tasks, particularly
those involving psychomotor and perceptual processing
speed. The pattern of results observed in the larger
group of 75 patients, which we reported at the 2000
Meeting of the Gerontological Association of America,
supports this initial, tentative conclusion and further
indicates that the beneficial impact of GHRH treatment
may be observed in other cognitive tasks that are less
dependent on processing speed.On the basis of the find-
ings of this larger, but still incomplete sample, we con-
clude that 5 months of daily GHRH treatment may
have a small,but significant,beneficial effect on the cog-
nitive abilities of healthy older men and women.These
preliminary findings support the hypothesis that the
age-related declines in the somatotrophic axis may be
related to declines in cognition, and that supplementa-
tion of this neurohormonal deficit may partially amelio-
rate such cognitive deficits.
Summary of study on chronic GHRH treatment
Overall,it appears that once-daily GHRH injections can
stimulate the desired increases in GH and IGF-I and
result in significant increases in LBM and declines in fat
mass, although these results are tempered by estrogen
status in women.Alone, however, they do not support
an indication for treatment unless these increases induce
meaningful changes in muscle mass and functional
capacity and other outcome measures.While GHRH
treatment produced a single large burst of GH secretion
immediately following each evening injection,a “youth-
ful” nighttime pulsatile GH secretion pattern was not
restored.This increase in overall GH and IGF-I levels
may suffice for some effects mediated through GH and
IGF-I (eg, changes in body composition and possibly
improvements in cognitive function),but it is far from a
restoration of nighttime pulsatile GH secretion, which
may be required to support any possible beneficial
effects on sleep quality.For this,a sustained-release for-
mulation or an analog with a duration of action of at
least 8 h will be needed. It must be emphasized that
these conclusions regarding the effects of GHRH treat-
ment are tentative,as more definitive results will not be
available until both studies are completed and analyzed.
Conclusions
Our preliminary results show that once-daily evening
subcutaneous injections of GHRH are well tolerated
and can increase 24-h GH secretion, boost circulating
levels of IGF-I,and improve body composition in older
patients. Preliminary analyses also suggest beneficial
effects on physical and cognitive performance.These
findings, while encouraging further study, are far from
the type of results that can support use of GHRH to
“treat” aging.
1,91 As aging is not a disease, drug therapy
cannot be encouraged until meaningful functional ben-
efits are shown either in treatment or in the prevention
of specific disorders associated with aging.The recent
preliminary report of a multicenter European study
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233showing that GH may accelerate recovery from hip frac-
ture
92 is an example of such a finding. Nevertheless, the
observed beneficial effects of GHRH and its minimal
side effects are encouraging and indicate that future
work in this area is well worth pursuing with the hope of
ultimately improving the overall health and quality of
life of the seniors, who currently represent the fastest-
growing segment of our population.❑
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El tratamiento de los cambios relacionados
con la edad a nivel de las hormonas
somatotróficas, del sueño y de la cognición
Muchos de los sistemas del organismo que fun-
cionan para mantener la salud y el bienestar en el
óptimo declinan a medida que avanza la edad. La
capacidad aeróbica, y la masa y la fuerza muscu-
lar declinan progresivamente. Las alteraciones sig-
nificativas del sueño se asocian con aumentos en
la morbilidad y en la mortalidad. La cognición
declina, afectando la capacidad del individuo
mayor para funcionar independientemente. Las
intervenciones que puedan al menos estabilizar o
posiblemente mejorar la capacidad funcional, la
calidad del sueño y la función cognitiva tienen
teóricamente el potencial de prolongar la capaci-
dad de un individuo mayor para vivir indepen-
dientemente, por lo que el interés en su posible
utilidad está creciendo rápidamente. Una de tales
intervenciones puede ser la estimulación del eje
“somatotrófico” a través de la hormona libera-
dora de hormona del crecimiento (GHRH). Aquí
nosotros revisamos la evidencia de tales interven-
ciones somatotróficas. Nosotros también damos
cuenta, a partir de dos grandes estudios de inter-
vención con GHRH (uno recientemente termina-
do y otro en curso), acerca de los hallazgos preli-
minares de los efectos del tratamiento crónico
con GHRH sobre las hormonas somatotróficas, la
composición del organismo, el estado funcional,
el sueño, y la función cognitiva del hombre y la
mujer mayores sanos.
Traitement des changements liés à l’âge au
niveau des hormones somatotropes, du
sommeil et de la cognition
La plupart des systèmes du corps humain dont la
fonction est de maintenir un état optimal de
bonne santé et de bien-être déclinent avec l’âge.
La capacité aérobie, la masse et la force muscu-
laires déclinent progressivement. Les troubles
significatifs du sommeil sont associés à une aug-
mentation de la mortalité et de la morbidité. Les
capacités cognitives diminuent, retentissant sur
l’autonomie des personnes âgées. Les interven-
tions thérapeutiques susceptibles de stabiliser
voire d’améliorer la capacité fonctionnelle, la
qualité du sommeil et les fonctions cognitives ont
en théorie le pouvoir de prolonger la capacité des
sujets âgés de vivre de façon indépendante et sus-
citent de ce fait un intérêt croissant. La stimula-
tion de l’axe somatotrope par l’intermédiaire de
la somatocrinine (growth hormone–releasing hor-
mone, GHRH) constitue l’une des modalités d'in-
tervention possibles. Cet article fait le point sur les
données concernant ce type de traitement. Nous
rapportons également les résultats préliminaires
de deux études, l’une en cours et l’autre récem-
ment achevée, portant sur les effets du traite-
ment chronique par GHRH sur les hormones
somatotropes, la composition corporelle, l’état
fonctionnel, le sommeil et la fonction cognitive
d’hommes et de femmes âgés en bonne santé.REFERENCES
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